Clinical trials: Metastasis to Brain of Primary Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04647916
- Testing
- Sacituzumab Govitecan
- Where
- 296 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Melanoma (Skin Cancer)
MELanoma Brain Metastasis Treated With CYberknife
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
- Trial name
- MELCY (NCT07691255)
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Brain Tumor, Brain Metastases
Re-craniotomy and Complications After Elective Neurosurgery
This study is a prospective cohort study to find the incidence of re-craniotomy and predictive factors. The secondary outcomes are to find the incidence of major non-neurological complications and predictive factors.
- Conditions
- Brain Tumor, Brain Metastases, Brain Cancer, Brain Neoplasms
- Trial name
- NCT03910556
- Testing
- Propofol
- Volunteers
- 439 people
- Sponsor
- Chiang Mai University
Cancer, Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic radiation for newly diagnosed brain metastases.
- Trial name
- RAD0102 (NCT00582075)
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases
Palbociclib and Pembrolizumab In Central Nervous System Metastases
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: Palbociclib alone (Cohort 1) The…
- Conditions
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
- Trial name
- NCT02896335
- Testing
- Palbociclib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain.
- Trial name
- NCT01494662
- Testing
- HKI-272, Surgical Resection, Capecitabine
- Where
- 18 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
Non Small Cell Lung Cancer, Brain Metastases
Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
- Trial name
- NCT04675008
- Testing
- Dacomitinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does…
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC)
- Trial name
- NCT02312622
- Testing
- Pegylated Irinotecan
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Joel Neal
Small Cell Lung Cancer
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
The purpose of the study is to determine the value of FLT-PET early after initiated chemotherapy in patients with small cell lung cancer, and to determine whether MRI of the brain should be performed routinely in these patients.
- Trial name
- SIBES II (NCT02995902)
- Testing
- FLT-PET, MRI
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lung Cancer, Breast Cancer
Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases
For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00581113
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Non-small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
- Trial name
- NCT02308020
- Testing
- Abemaciclib
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
This study aims to show that brain metastases from Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancers are able to be controlled by local therapies, Stereotactic Radiosurgery (SRS) and/or Neurosurgery…
- Trial name
- Local HER-O (NCT02898727)
- Testing
- Local Therapy
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Non-Small Cell Lung Cancer, Leptomeningeal Metastases
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or…
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Trial name
- NCT02616393
- Testing
- Tesevatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kadmon Corporation, LLC
Cancer, Metastasis
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and…
- Conditions
- Cancer, Metastasis, Metastatic Cancer, Brain Metastases
- Trial name
- ADORATION (NCT05789589)
- Testing
- Azeliragon, Stereotactic radiosurgery, Corticosteroid
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Baptist Health South Florida
Mammary Neoplasms, Human
The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.
This study was a single-arm, open-label, phase II study of breast cancer patients with brain metastases. Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and…
- Trial name
- NCT05781633
- Testing
- eutidrone etoposide bevacizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Bladder Cancer
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
The goal of this clinical research study is to learn if whole brain radiation can lower the chances of developing brain tumors in patients with small cell carcinoma of the urinary tract, including the bladder.
- Trial name
- NCT00756639
- Testing
- Prophylactic Cranial Irradiation (PCI), Brain X-ray
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Metastatic Cancer
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment.
- Trial name
- NCT00398437
- Testing
- trastuzumab, chemotherapy, magnetic resonance imaging
- Where
- 3 sites in Belgium
- Volunteers
- 96 people
- Sponsor
- Jules Bordet Institute
HER2+ Metastatic Breast Cancer
Asciminib in HER2+ Breast Cancer Brain Metastases
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
- Trial name
- ASCENdANT (NCT07136428)
- Testing
- Asciminib and Trastuzumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University